• Korean Journal of Acupuncture
• /
• v.33 no.3
• /
• pp.131-138
• /
• 2016

Objectives : To assess and compare the effectiveness of acupuncture treatment of depression in Cancer patient's Home Caregivers. Methods : Total 60 cases in Cancer patient's Home Caregivers, who fulfilled the study's eligibility criteria, were recruited and observed(N=40). The individuals were assigned into two groups, the Acupuncture group(N=20) and Control group(N=20). Changes in their Hamilton Depression rating Scale indices, were statistically compared before and after treatment in order to investigate the effectiveness of treatment. Results : 70% Home Caregivers were female and 30% were male, half of the Home Caregivers was patient's spouse or partner and employee. After 6 weeks, Acupuncture group seems to show reduction in the Hamilton Depression Rating Scale. On the other hand after 8 weeks Control group do not show reduction in the Hamilton Depression rating Scale. Conclusions : The results suggest that acupuncture treatment may provide short-term relief of depressive symptoms in Home Caregivers for Cancer patients. Findings from this non-randomized trial should be interpreted with caution.

• Journal of Pharmacopuncture
• /
• v.14 no.4
• /
• pp.33-37
• /
• 2011

Objectives: To report the effect of cultivated wild ginseng pharmacopuncture on the lung cancer patient. Methods: Treatment of cultivated wild ginseng pharmacopuncture was conducted on the patient during 7 months. Pharmacopuncture therapy was done twice a week with a dosage of 2ml per each treatment. Computed Topography(CT) was performed to evaluate the therapeutic efficacy. Results: After the treatment of 7 months, chest CT revealed the mass size was decreased. Conclusions: This case provides us a possibility that cultivated wild ginseng pharmacopuncture offers potential benefits for lung cancer patient.

• The Korean Journal of Pain
• /
• v.5 no.1
• /
• pp.96-98
• /
• 1992

In early stages, cancer is not usually painful. However, many patients with recurrent or metastatic cancer eventually experience pain, which becomes progressively worse. Chemotherapy, sympathetic surgery, physical therapy and nerve block can be used to control cancer pain. A 60-year old patient had severe pain of the soft palate due to squamous cell carcinoma. We successfully treated this patient with maxillary nerve block using pure alcohol by a lateral approach. Four months after maxillay nerve block, the patient is still pain free.

• Journal of Korean Traditional Oncology
• /
• v.19 no.1
• /
• pp.61-68
• /
• 2014

Objectives : To study the effect of SB injection on tumor size in an advanced non-small cell lung cancer patient. Methods : A patient was clinically diagnosed as advanced non-small cell lung cancer (Stage IIIa). Four cycles of intravenous SB injection were conducted. Each cycle lasted 4 days. The content of 7vials SB was injected every day. To compare the tumor size before treatment and after four cycles of SB injection, chest computed tomography (CT) was performed. Results : Follow-up CT images showed that the tumor size was reduced. In admission, size of the tumor $6.7{\times}8.5{\times}9.5cm$ on the left lower lobe of lung. After SB injection, size of the tumor $5.6{\times}6.8{\times}8.4cm$ by Chest CT. The patient's symptoms such as cough, sputum were improving until four cycles of SB injection. Numerical rating scale (NRS) showed improvement of Chest pain from point 3 to point 0. Conclusions : This case study suggests that intravenous SB injection may have significant effects of anti-tumor for non-small cell lung cancer.

• Molecules and Cells
• /
• v.39 no.2
• /
• pp.77-86
• /
• 2016

Cancer is a heterogeneous disease caused by diverse genomic alterations in oncogenes and tumor suppressor genes. Despite recent advances in high-throughput sequencing technologies and development of targeted therapies, novel cancer drug development is limited due to the high attrition rate from clinical studies. Patient-derived xenografts (PDX), which are established by the transfer of patient tumors into immunodeficient mice, serve as a platform for co-clinical trials by enabling the integration of clinical data, genomic profiles, and drug responsiveness data to determine precisely targeted therapies. PDX models retain many of the key characteristics of patients' tumors including histology, genomic signature, cellular heterogeneity, and drug responsiveness. These models can also be applied to the development of biomarkers for drug responsiveness and personalized drug selection. This review summarizes our current knowledge of this field, including methodologic aspects, applications in drug development, challenges and limitations, and utilization for precision cancer medicine.

• Journal of the Korean Association of Oral and Maxillofacial Surgeons
• /
• v.47 no.5
• /
• pp.388-393
• /
• 2021

At present, in Korea, due to developments in medicine and technology and an increasing mean lifespan, the expected lifetime for elderly people is increasing (at 70 years, the expected additional lifespan is 14.8 years for males and 18.3 years for females). However, among all causes of death, malignant neoplasm is ranked first for all ages. Further, the incidence rate of oral cancer tends to increase with age. Thus, oral and maxillofacial surgeons have increased opportunity to experience the 'oldest old' patients with oral cancer. Elderly patients commonly have several comorbidities, poor general condition, limited socioeconomic support, fear of various postoperative complications, and perception of short for the rest of their life. In this situation, the patient, caregiver, and surgeon often choose undergraded treatment rather than standard treatment for oral squamous cell carcinoma owing to patient age. In elderly patients with oral cancer, ablation of tumor or reconstructive surgery is challenging for surgeons. Oral and maxillofacial surgeons must evaluate carefully the patient's medical condition and make a decision regarding treatment plans after sufficient discussion with patient and caregivers. We review the literature to consider the factors involved for deciding on a treatment plan regarding surgery in elderly patients with oral cancer.

• Journal of Hospice and Palliative Care
• /
• v.2 no.2
• /
• pp.138-143
• /
• 1999

Accurately estimating survival times in terminal cancer patients is very difficult for palliative care clinicians. But a reasonably accurate estimate of survival would permit the medical team to : Plan the ideal therapeutic strategy between overtreatment and too early discontinuation of specific therapy. Answer any questions asked by the patient or family. Organize adequate assistance for the patient concerned. Decide on the eligibility of the patient for clinical trials and whether to begin a treatment, the effects of which will not be immediate. This case was a 79 year-old male patient with colon cancer. He complained of dry mouth, anorexia, weight loss and showed KPS $40{\sim}50$ on admission day. 40 days later he died. To improve patient/family quality of life, it is necessary to improve the ability to estimate accurately a patient's length of survival.

• Journal of Gastric Cancer
• /
• v.19 no.3
• /
• pp.235-253
• /
• 2019

Gastric cancer (GC) is one of the deadliest malignancies in the world. Currently, clinical treatment decisions are mostly made based on the extent of the tumor and its anatomy, such as tumor-node-metastasis staging. Recent advances in genome-wide molecular technology have enabled delineation of the molecular characteristics of GC. Based on this, efforts have been made to classify GC into molecular subtypes with distinct prognosis and therapeutic response. Simplified algorithms based on protein and RNA expressions have been proposed to reproduce the GC classification in the clinical field. Furthermore, a recent study established a single patient classifier (SPC) predicting the prognosis and chemotherapy response of resectable GC patients based on a 4-gene real-time polymerase chain reaction assay. GC patient stratification according to SPC will enable personalized therapeutic strategies in adjuvant settings. At the same time, patient-derived xenografts and patient-derived organoids are now emerging as novel preclinical models for the treatment of GC. These models recapitulate the complex features of the primary tumor, which is expected to facilitate both drug development and clinical therapeutic decision making. An integrated approach applying molecular patient stratification and patient-derived models in the clinical realm is considered a turning point in precision medicine in GC.

• Journal of Digestive Cancer Research
• /
• v.2 no.1
• /
• pp.15-20
• /
• 2014

Cancer, especially GI cancer itself and any associated treatments have profound effect on the patient's nutritional status. It is therefore very important to understand various nutritional issues in GI cancer patients for the cure and for increasing the compliance during the course of the treatment. Screening and identification of nutritional risk for the GI cancer patients is very essential and is plays a critical part of the treatment to help improve patient outcomes. Maintaining optimal nutritional status is an important goal in the management of individuals diagnosed, treated with cancer. Maintenance of adequate nutritional intake is important whether patients are undergoing active therapy, recovering from cancer therapy, or are in remission and striving to avoid cancer recurrence. The goals of nutrition therapy are to prevent or reverse nutrient deficiencies, preserve lean body mass, help patients better tolerate treatments and minimize nutrition-related side effects and complications, etc. Recent interest in clinical settings is also in maximizing quality of life of the patients which can also be modulated by appropriate nutrition.

• Asian Pacific Journal of Cancer Prevention
• /
• v.15 no.4
• /
• pp.1627-1632
• /
• 2014

Background: Several studies indicated that the diagnosis season affects the prognosis of some cancers, such as examples in the prostate, colon and breast. This retrospective study aimed to investigate whether the diagnosis and recurrent season impacts the prognosis of epithelial ovarian cancer patients. Methods: From January 2005 to August 2010, 161 epithelial ovarian cancer patients were analyzed and followed up until August 2013. Kaplan-Meier survival curves and the log-rank test were used to make the survival analysis. Multivariate analysis was conducted to identify independent prognostic factors. Results: The prognostic factors of overall survival in epithelial ovarian cancer patients included age, clinical stage, pathological type, histological grade, residual disease after primary surgery, recurrent season and adjuvant chemotherapy cycles. Moreover, clinical stage, histological grade, residual disease after primary surgery, recurrent season and adjuvant chemotherapy cycles also impacted the progression-free survival of epithelial ovarian cancer patients. The diagnosis season did not have a significantly relationship with the survival of operable epithelial ovarian cancer patients. Median overall survival of patients with recurrent month from April to November was 47 months, which was longer (P < 0.001) than that of patients with recurrence month from December to March (19 months). Median progression-free survival of patients with recurrence month from April to November and December to March was 20 and 8 months, respectively (P < 0.001). Conclusion: The recurrence season impacts the survival of epithelial ovarian cancer patients. However, the diagnosed season does not appear to exert a significant influence.